Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 257049

Drug Profile

GSK 257049

Alternative Names: 257049; Circumsporozoite protein hepatitis-B surface antigen fusion protein- GSK; CSP-HBsAg - GSK; CSP-HBsAg/SBAS2-GSK; FSV-1-malaria-vaccine-GSK; GSK-257146; GSK-RTS,S/AS01; GSK257049; Malaria vaccine 257049 - GSK; Mosquirix; Plasmodium falciparum circumsporozoite protein/HBsAg subunit vaccine - GSK; Plasmodium falciparum CSP/HBsAg - GSK; Plasmodium falciparum CSP/HBsAg subunit vaccine - GSK; Plasmodium falciparum malaria vaccine 257049; Profilam; QS 21 stimulon adjuvanted malaria vaccine - Agenus/GSK; RTS,S; RTS,S/AS; RTS,S/AS01; RTS,S/AS01B; RTS,S/AS01E; RTS,S/AS02; RTS,S/AS02A; RTS,S/AS02D; SB-257049

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK; Malaria Vaccine Initiative; PATH; University of Oxford
  • Class Antimalarials; Parasitic vaccines; Subunit vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Falciparum malaria

Most Recent Events

  • 11 Nov 2022 GlaxoSmithKline completes a phase II trial in Falciparum malaria (In infants, Prevention) in Ghana and Kenya (IM) (NCT03276962)
  • 06 Sep 2022 WHO grants prequalification to GSK 257049 for Falciparum malaria
  • 17 Aug 2022 GlaxoSmithKline and PATH completes a phase II trial in Falciparum malaria (In adults, Prevention) in Kenya (IM) (NCT04661579)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top